DDInter1174 DDInter927
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Methotrexate {u} (Compound) resembles {v} (Compound) Raltitrexed
Methotrexate {u} (Compound) resembles {v} (Compound) Tetrahydrofolic acid
Methotrexate {u} (Compound) treats {v} (Disease) stomach cancer
Methotrexate {u} (Compound) binds {v} (Gene) SLC16A1
Methotrexate {u} (Compound) upregulates {v} (Gene) PDLIM1
Methotrexate {u} (Compound) is included by {v} (Pharmacologic Class) Folic Acid Metabolism Inhibitors
Methotrexate {u} (Compound) downregulates {v} (Gene) TMEM50A
Methotrexate {u} (Compound) causes {v} (Side Effect) Ecchymosis
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Haloperidol
Methotrexate (Compound) resembles Raltitrexed (Compound)
Methotrexate (Compound) resembles Tetrahydrofolic acid (Compound)
Methotrexate (Compound) treats stomach cancer (Disease)
Methotrexate (Compound) binds SLC16A1 (Gene)
Methotrexate (Compound) upregulates PDLIM1 (Gene)
Methotrexate (Compound) is included by Folic Acid Metabolism Inhibitors (Pharmacologic Class)
Methotrexate (Compound) downregulates TMEM50A (Gene)
Methotrexate (Compound) causes Ecchymosis (Side Effect)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Haloperidol